Related Experiment Video
Updated: Jul 27, 2025
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact
Hitomi Hosoya1, Paula Rodriguez-Otero2, Surbhi Sidana1
1Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA.
Abstract:
Despite recent advancement of treatment strategies in multiple myeloma (MM), patients with relapsed/refractory MM disease, particularly after triple-class refractoriness, continue to have poor prognosis. Chimeric antigen receptor (CAR-T) cells were developed and applied to improve outcomes in this setting, and two products, idecabtagene vicleucel and ciltacabtagene autoleucel, both targeting B-cell maturation antigen, have been approved by the Food and Drug Administration in the United States and European Medicines Agency in Europe. Both have shown unprecedented clinical outcomes with high response rate and prolonged progression-free survival and overall survival in this patient population with grim prognosis. Currently, further investigations are ongoing for CAR-T targeting different tumor antigens such as G protein-coupled receptor, class C, group 5, member D or with different combinations of intracellular signaling domains, as well as fourth-generation CAR-T with antigen-unrestricted inducible cytokines. Although CAR-T therapies hold hopes and enthusiasm from the myeloma community, several hurdles remain before these treatments become available for all patients in need. These barriers include CAR-T-cell manufacturing availability, access to administering centers, financial cost, caregivers' availability, and socioeconomic and racial disparities. Expanding clinical trial eligibility criteria and real-world data collection and analysis is crucial to understand the efficacy and safety of CAR-T in the patient cohort who tends to be excluded from current trials.
Insights
Chimeric antigen receptor (CAR-T) cell therapy offers new hope for relapsed/refractory multiple myeloma patients. Despite high efficacy, challenges like cost and access limit widespread use, necessitating broader clinical trial inclusion.
Area of Science:
- Hematology/Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Multiple myeloma (MM) patients with relapsed/refractory disease, especially after triple-class refractoriness, face poor prognoses.
- Existing treatments have limitations for this patient subset.
- Chimeric antigen receptor (CAR-T) cell therapy has emerged as a promising treatment modality.
Purpose of the Study:
- To review the advancements and approved CAR-T cell therapies targeting B-cell maturation antigen (BCMA) for multiple myeloma.
- To discuss ongoing research into novel CAR-T targets and next-generation designs.
- To identify and address the barriers hindering universal access to CAR-T therapy.
Main Methods:
- Review of approved CAR-T cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel) targeting BCMA.
- Discussion of current investigations into alternative CAR-T targets (e.g., GPRC5D) and advanced CAR designs.
- Analysis of practical challenges impacting CAR-T therapy accessibility.
Main Results:
- Approved BCMA-targeted CAR-T therapies demonstrate unprecedented clinical outcomes, including high response rates and prolonged survival in refractory MM.
- Ongoing research explores new targets and enhanced CAR-T cell functionalities.
- Significant barriers to CAR-T therapy include manufacturing, cost, access to centers, and socioeconomic/racial disparities.
Conclusions:
- CAR-T cell therapy represents a significant breakthrough for patients with relapsed/refractory multiple myeloma.
- Addressing manufacturing, cost, access, and equity issues is critical for broader patient benefit.
- Expanding clinical trial eligibility and collecting real-world data are essential for optimizing CAR-T therapy in diverse MM populations.
More Related Videos
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019